This record was last updated August 5, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
Main objective of this study is to describe the evolution of infusion settings (base, high and low infusion rates) of foslevodopa/foscarbidopa subcutaneous infusion (LDp/CDp) at different timepoints in the treatment of advanced Parkinson's disease (aPD) as captured in ONE-CRM.
Protocol Amendment History
3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-17; most recent amendment 2025-08-01.
Status change: Not Yet Recruiting → Recruiting2025-05-12